B O O K - American College of Rheumatology

A412
Cell Death: Receptors, Sensors and Inflammatory
Pathways R
Moderators: Keith B. Elkon, MD; University of Washington;
Seattle, WA
Dror Mevorach, MD; Hadassah University Hospital; Jerusalem,
Israel
2:30 PM
TAM Receptors and Innate Immune Function
Greg E. Lemke, PhD; Salk Institute; La Jolla, CA
3:00 PM
Intracellular Sensors of Nucleic Acids and the Regulation of
Innate Immunity by microRNAs
Luke A. O’Neill, PhD; Trinity College Dublin; Dublin, Ireland
3:30 PM
Necrosis and Inflammation - Pathways Uncovered
Kenneth L. Rock, MD; University of Massachusetts; Worcester,
MA
Session Overview:
Autoimmune responses in systemic and, perhaps, some
organ-specific diseases are thought to arise from stimulation
by self antigen derived from dead or dying cells. Recent
studies have elucidated specific cellular receptors as well as
intracellular sensors that recognize distinct products of dying
cells. Depending on which receptors and sensors are triggered,
different patterns of cytokine are produced resulting in
suppression or enhancement of immune response to self.
3:30 PM
New Treatments and Beyond for Acute and Chronic Gout
Robert Terkeltaub, MD; VA Medical Center; San Diego, CA
Session Overview:
Gout is a common disease. Treatment protocols have been
unchanged for many years. However, there remain patients who
are difficult to treat due to co-morbidities. Further, advances in
diagnosis, and new and potential therapeutic agents justify an
examination of how these options can be applied currently and
in the future.
Upon completion of this session, participants should be able to:
• develop treatment strategies for patients with co-morbidities
• explain novel diagnostic modalities in gout
• assess new treatment options for gout
Hall A3
Rheumatoid Arthritis Treatment 2010: Traditional
DMARDs, Biologic DMARDs and Newer Treatment
Strategies C PM PS
Moderators: Thomas P. Olenginski, MD; Geisinger Medical
Center; Danville, PA
John M. Davis, MD; Mayo Clinic; Rochester, MN
2:30 PM
Non-biologic Rheumatoid Arthritis Therapy: Traditional
DMARDs
James R. O’Dell, MD; University of Nebraska Medical Center;
Omaha, NE
wednesday
Upon completion of this session, participants should be able to:
• describe the different effects of apoptotic and necrotic cells
on immune cell function
• identify which molecules are critically involved in engaging
cellular responses
• explain how different receptors and intracellular sensors cells
trigger anti- or pro-inflammatory responses in macrophages
and dendritic cells
• discuss how aberrations in these pathways lead to systemic
autoimmune responses
ACR Clinical Symposia
2:30 - 4:00 PM
Sidney J. Marcus Auditorium
Crystallizing Your Assessment and Treatment of
Difficult to Treat Gout C PM PS
Moderators: Bruce I. Hoffman, MD; Philadelphia, PA
Naomi Schlesinger, MD; University of Medicine and Dentistry
of New Jersey/Robert Wood Johnson Medical School; New
Brunswick, NJ
2:30 PM
Treatment of Gout in the Difficult Patient-Transplant, and other
Co-morbidities
N. Lawrence Edwards, MD; University of Florida; Gainesville, FL
3:00 PM
New and Old Modalities Used to Diagnose Gout
Naomi Schlesinger, MD; University of Medicine and Dentristry
of New Jersery/Robert Wood Johnson Medical School; New
Brunswick, NJ
3:00 PM
Biologic DMARD Therapy in Rheumatoid Arthritis: Applying an
Expanded Arsenal
Josef S. Smolen, MD; Krankenhaus Lainz; Vienna, Austria
3:30 PM
Newer Rheumatoid Arthritis Treatment Strategies
Duncan Porter, MD; Gartnavel General Hospital; Glasgow, United
Kingdom
Session Overview:
Since 1998, the use of new, targeted biologic therapies has
revolutionized the treatment of rheumatoid arthritis. Currently,
agents that inhibit the action of tumor necrosis factor alpha,
IL-1, IL-6, as well as selective co-stimulatory blockade and B-cell
depleting therapies are available. However, early diagnosis and
use of methotrexate, sulfasalazine, or hydroxychloroquine still
constitute many initial treatment strategies. In 2008, the ACR
published recommendations for the use of non-biologic and
biologic disease-modifying antirheumatic drugs in rheumatoid
arthritis. Rheumatologists have an expanded treatment arsenal
and seek to apply the best evidence to treat their patients.
Upon completion of this session, participants should be able to:
• define the role and supportive evidence for non-biologic
DMARD treatment in rheumatoid arthritis
• appraise rheumatoid arthritis treatment goals and the current
ACR treatment recommendations
• assess the evidence supporting biologic DMARD therapy
• review data from combination DMARD therapy
• determine situations where DMARD may be tapered and/or
withdrawn
114
2010 Program Book